Research into bone regeneration has taken a major leap forward with the discovery of a critical mechanism that could transform treatments for bone disorders. Scientists have identified how Discoidin Domain Receptor 2 (DDR2) enhances Bone Morphogenetic Protein (BMP)-dependent bone regeneration while mitigating the risk of heterotopic ossification (HO), offering promising therapeutic opportunities. This discovery sheds light on how DDR2 regulates BMP activity, paving the way for safer and more effective interventions in bone repair and related conditions.
Bone loss resulting from trauma, fracture or disease is a major global health challenge, often leading to long-term disability. Bone Morphogenetic Proteins (BMPs) are known for their essential role in bone formation and healing, yet their clinical use is hampered by significant obstacles. High doses of BMPs are often required, which carry risks of toxicity and potential tumorigenesis, while their unregulated action can lead to abnormal bone formation in soft tissues, known as heterotopic ossification. Addressing these challenges requires a deeper understanding of the factors that modulate BMP signaling, highlighting the urgent need to identify mechanisms that can enhance bone regeneration while minimizing adverse effects.
On January 2, 2025, a study (DOI: 10.1038/s41413-024-00391-z) published in Bone research revealed the central role of Discoidin Domain Receptor 2 (DDR2) in BMP signaling. Conducted by a team at the University of Michigan School of Dentistry, the research shows that DDR2 is not only essential for efficient bone regeneration, but is also involved in heterotopic ossification. This discovery establishes DDR2 as a critical regulator of BMP activity, with profound implications for bone biology and therapeutic development.
The researchers used an integrated approach to examine the role of DDR2 in BMP signaling. By implanting BMP2 subcutaneously in mice, they observed significantly reduced bone formation in Ddr2-deficient mice. In a mouse model of fibroblastic osteoplastic progressive (FOP)—a genetic condition that causes abnormal bone growth in soft tissues—DDR2 deficiency significantly reduced heterotopic ossification. Interestingly, DDR2 was found to be co-expressed with GLI1, a skeletal stem cell marker, in cells migrating into BMP2 implants. These DDR2/GLI1-positive cells contributed significantly to bone formation, affecting cartilage and bone lineages equally. Further experiments revealed that selective ablation of DDR2 in Gli1-expressing cells produced bone formation deficits similar to those observed in globally Ddr2-deficient animals, primarily due to reduced proliferation of Gli1+ cells rather than apoptosis. Specifically, DDR2 was shown to regulate YAP and TAZ, two key components of the Hippo pathway, highlighting its role in orchestrating BMP responses through the collagen matrix.
Our findings highlight the importance of DDR2 in modulating BMP signaling. This discovery not only deepens our understanding of bone biology, but also opens up exciting possibilities for therapeutic interventions to enhance bone regeneration and treat conditions such as heterotopic ossification.”
Renny T. Franceschi, Ph.D., Professor, University of Michigan School of Dentistry and senior author of the study
The potential applications of this research are groundbreaking. By identifying DDR2 as a critical regulator of BMP activity, scientists can develop new therapies to improve bone regeneration in clinical contexts such as fracture healing and spinal fusions. Additionally, these findings offer hope for the treatment of debilitating conditions such as FOP, where abnormal bone formation severely affects quality of life. This study represents a transformative step forward, ensuring the safer and more targeted use of BMPs to promote bone repair and regeneration.
Source:
Journal Reference:
Wu, F., et al. (2025). Discoidin domain receptor 2 is an important regulator of BMP signaling during heterotopic bone formation. Bone research. doi.org/10.1038/s41413-024-00391-z.
